- Home
- FINS vs LRMR Comparison
FINS vs LRMR Comparison
Compare FINS & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINS
- LRMR
- Stock Information
- Founded
- FINS 2019
- LRMR N/A
- Country
- FINS United States
- LRMR United States
- Employees
- FINS N/A
- LRMR N/A
- Industry
- FINS Finance/Investors Services
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- FINS Finance
- LRMR Health Care
- Exchange
- FINS Nasdaq
- LRMR Nasdaq
- Market Cap
- FINS 447.8M
- LRMR 360.3M
- IPO Year
- FINS N/A
- LRMR N/A
- Fundamental
- Price
- FINS $13.09
- LRMR $4.31
- Analyst Decision
- FINS
- LRMR Strong Buy
- Analyst Count
- FINS 0
- LRMR 7
- Target Price
- FINS N/A
- LRMR $16.71
- AVG Volume (30 Days)
- FINS 78.0K
- LRMR 3.1M
- Earning Date
- FINS 01-01-0001
- LRMR 11-14-2025
- Dividend Yield
- FINS 9.97%
- LRMR N/A
- EPS Growth
- FINS N/A
- LRMR N/A
- EPS
- FINS N/A
- LRMR N/A
- Revenue
- FINS N/A
- LRMR N/A
- Revenue This Year
- FINS N/A
- LRMR N/A
- Revenue Next Year
- FINS N/A
- LRMR N/A
- P/E Ratio
- FINS N/A
- LRMR N/A
- Revenue Growth
- FINS N/A
- LRMR N/A
- 52 Week Low
- FINS $11.61
- LRMR $1.61
- 52 Week High
- FINS $12.57
- LRMR $9.50
- Technical
- Relative Strength Index (RSI)
- FINS 46.91
- LRMR 50.70
- Support Level
- FINS $12.98
- LRMR $3.87
- Resistance Level
- FINS $13.20
- LRMR $4.48
- Average True Range (ATR)
- FINS 0.13
- LRMR 0.29
- MACD
- FINS 0.00
- LRMR -0.01
- Stochastic Oscillator
- FINS 50.57
- LRMR 61.48
About FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest
Angel Oak Financial Strats Income Term is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.